CLAIM AMENDMENTS

1. (currently amended): A compound according to Formula I:



wherein, W is a nitrogen atom and Y is void, or, W is a carbon atom and Y=H;

R^1 to R^7 may be the same or different and are independently hydrogen or straight, branched or cyclic C_{1-6} alkyl;

R^8 is an optionally substituted heterocyclic group or an optionally substituted aromatic group

Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

n and n' are independently, 0-2;

X is a group of the formula:



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted nitrogen atom and wherein any heteroatom in addition to P in ring A ~~or B~~ is N;

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a $(CH_2)_{n''}$ group (where n''= 1-2), or V is a C=O group; and

wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted C_{1-6} alkyl group; an optionally substituted aromatic or heterocyclic group; ~~a C_{1-6} alkyl group substituted with an optionally substituted aromatic or heterocyclic group;~~ an optionally substituted amino group; an optionally substituted C_{1-6} alkylamino or C_{3-7} cycloalkylamino group; ~~a sulfonyl group~~ and an optionally substituted carbonyl group; or

the pharmaceutically acceptable acid addition salts thereof;

including said compound in any stereoisomeric form and any mixture of stereoisomeric forms thereof;

wherein Ring B is selected from the group consisting of: benzene and a 5 to 7-membered cycloalkyl ring; and the optionally substituted forms thereof.

2. (previously amended): The compound of claim 1, wherein Ring A is selected from the group consisting of: pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; and triazole and the optionally substituted forms thereof.

F1

3. (canceled)

3 ~~4.~~ (previously amended): The compound of claim 1, wherein Ring B is selected from the group consisting of: cyclopentyl; cyclohexyl; cycloheptyl; cyclopentenyl; cyclohexenyl; and cycloheptenyl and the optionally substituted forms thereof.

5. (canceled)

4 ~~6.~~ (previously amended): The compound of claim 1, wherein Ring A and Ring B together are optionally substituted dihydroquinoline or tetrahydroquinoline.

5 ~~7.~~ (previously amended): The compound of claim 1, wherein Ring A and Ring B are independently optionally substituted with a substituent selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

8-11. (canceled)

6 ~~12.~~ (previously amended): The compound of claim 1 wherein said optional substituent in Ring A or Ring B is independently an optionally substituted aralkyl or

heterocycloalkyl, wherein said heterocycloalkyl is a 5 or 6 membered ring containing 1-4 heteroatoms.

7 6
~~13.~~ (previously amended): The compound of claim ~~12~~, wherein said optionally substituted aralkyl or heterocycloalkyl is selected from the group consisting of: phenylC_{1-4}alkyl; phenylmethyl (benzyl); phenethyl; pyridinylmethyl; and pyridinylethyl.

14-50. (canceled)

8
~~51.~~ (previously amended): The compound of claim 1, wherein Z is an optionally substituted C_{1-6}alkyl group, wherein said C_{1-6}alkyl group is substituted with one or more substituents selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

52-54. (canceled)

9
~~55.~~ (previously amended): The compound of claim 1, wherein Z is an optionally substituted aromatic or heterocyclic group or a C_{1-6}alkyl group optionally substituted with an optionally substituted aromatic or heterocyclic group.

10 9
~~56.~~ (previously amended): The compound of claim ~~55~~, wherein said optionally substituted aromatic group is substituted with a substituent selected from the group consisting of: benzene; naphthalene; dihydronaphthalene; and tetrahydronaphthalene; and wherein said optionally substituted heterocyclic group is a 5 to 6-membered saturated, partially saturated, or aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.

11 10
~~57.~~ (original): The compound of claim ~~56~~, wherein said heterocyclic group is selected from the group consisting of: pyridine, quinoline, isoquinoline, imidazole,

benzimidazole, azabenzimidazole, benzotriazole, furan, benzofuran, thiazole, benzothiazole, oxazole, benzoxazole, pyrrole, indole, indoline, indazole, pyrrolidine, pyrrolidone, pyrroline, piperidine, piperazine, tetrahydroquinoline, tetrahydroisoquinoline, pyrazole, thiophene, isoxazole, isothiazole, triazole, tetrazole, oxadiazole, thiadiazole, morpholine, thiamorpholine, pyrazolidine, imidazolidine, imidazoline, tetrahydropyran, dihydropyran, benzopyran, dioxane, dithiane, tetrahydrofuran, tetrahydrothiophene, dihydrofuran, and dihydrothiophene.

12 11
~~58.~~ (previously amended): The compound of claim ~~57~~, wherein said heterocyclic group contains nitrogen or sulfur heteroatoms; and wherein said nitrogen or sulfur heteroatoms are optionally in the form of oxides.

59-97. (canceled)

F1 13
~~98.~~ (currently amended): A compound selected from the group consisting of:

(a) AMD8862, N-(2-pyridinylmethyl)-N'-[2-[(1*H*-imidazol-4-ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzene dimethanamine;

(b) AMD8887, N-(2-pyridinylmethyl)-N'-[2-[(1*H*-imidazol-2-ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(c) AMD8816, N-(2-pyridinylmethyl)-N'-[2-(phenylureido)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(d) AMD8737, N-(2-pyridinylmethyl)-N'-[[N"-(n-butyl)carboxamido]methyl] -N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(e) AMD8739, N-(2-pyridinylmethyl)-N'-(carboxamidomethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(f) AMD8752, N-(2-pyridinylmethyl)-N'-[(N"-phenyl)carboxamidomethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(g) AMD8765, N-(2-pyridinylmethyl)-N'-(carboxymethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(h) AMD8715, N-(2-pyridinylmethyl)-N'-(phenylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(i) AMD8907, N-(2-pyridinylmethyl)-N'-(1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(j) AMD8927, N-(2-pyridinylmethyl)-N'-(5,6-dimethyl-1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine ~~(hydrobromide salt)~~;

(k) AMD8926, N-(2-pyridinylmethyl)-N'-(5-nitro-1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(l) AMD8929, N-(2-pyridinylmethyl)-N'-[(1*H*)-5-azabenzimidazol-2-ylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(m) AMD8931, N-(2-pyridinylmethyl)-N-(4-phenyl-1*H*-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(n) AMD8783, N-(2-pyridinylmethyl)-N'-[2-(2-pyridinyl)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(o) AMD8764, N-(2-pyridinylmethyl)-N'-(2-benzoxazolyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(p) AMD8780, N-(2-pyridinylmethyl)-N'-(*trans*-2-aminocyclohexyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(q) AMD8818, N-(2-pyridinylmethyl)-N'-(2-phenylethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(r) AMD8829, N-(2-pyridinylmethyl)-N'-(3-phenylpropyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(s) AMD8839, N-(2-pyridinylmethyl)-N'-(*trans*-2-aminocyclopentyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(t) AMD8726, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-glycinamide;

(u) AMD8738, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-alaninamide;

(v) AMD8749, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-aspartamide;

(w) AMD8750, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-pyrazinamide;

(x) AMD8740, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-prolinamide;

(y) AMD8741, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)-lysinamide;

(z) AMD8724, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-benzamide;

(aa) AMD8725, N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-picolinamide;

(bb) AMD8713, N'-Benzyl-N-[[4-[[(2-pyridinylmethyl) amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-urea;

(cc) AMD8712, N'-phenyl-N-[[4-[[(2-pyridinylmethyl) amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-urea;

(dd) AMD8716, N-(6,7,8,9-tetrahydro-5*H*-cyclohepta[~~*bacteria*~~b]pyridin-9-yl)-4-[[(2-pyridinylmethyl)amino]methyl]benzamide;

(ee) AMD8717, N-(5,6,7,8-tetrahydro-8-quinolinyl)-4-[[(2-pyridinylmethyl)amino]methyl]benzamide;

(ff) AMD8634, N,N'-bis(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(gg) AMD8774, N,N'-bis(2-pyridinylmethyl)-N'-(6,7,8,9-tetrahydro-5*H*-cyclohepta[~~*bacteria*~~b]pyridin-9-yl)-1,4-benzenedimethanamine;

(hh) AMD8775, N,N'-bis(2-pyridinylmethyl)-N'-(6,7-dihydro-5*H*-cyclopenta[~~*bacteria*~~b]pyridin-7-yl)-1,4-benzenedimethanamine;

(ii) AMD8819, N,N'-bis(2-pyridinylmethyl)-N'-(1,2,3,4-tetrahydro-1-naphthalenyl)-1,4-benzenedimethanamine;

(jj) AMD8768, N,N'-bis(2-pyridinylmethyl)-N'-[(5,6,7,8-tetrahydro-8-quinolinyl)methyl]-1,4-benzenedimethanamine;

(kk) AMD8767, N,N'-bis(2-pyridinylmethyl)-N'[(6,7-dihydro-5*H*-cyclopenta[~~*bacteria*~~b]pyridin-7-yl)methyl]-1,4-benzenedimethanamine;

(ll) AMD8838, N-(2-pyridinylmethyl)-N-(2-methoxyethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(mm) AMD8871, N-(2-pyridinylmethyl)-N-[2-(4-methoxyphenyl)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(nn) AMD8844, N,N'-bis(2-pyridinylmethyl)-1,4-(5,6,7,8-tetrahydro-8-quinolinyl)benzenedimethanamine;

(oo) AMD7129, N-[(2,3-dimethoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(pp) AMD7130, N,N'-bis(2-pyridinylmethyl)-N-[1-(N"-phenyl-N"-methylureido)-4-piperidinyl]-1,3-benzenedimethanamine;

(qq) AMD7131, N,N'-bis(2-pyridinylmethyl)-N-[N"-p-toluenesulfonylphenylalanyl)-4-piperidinyl]-1,3-benzenedimethanamine;

(rr) AMD7136, N,N'-bis(2-pyridinylmethyl)-N-[1-[3-(2-chlorophenyl)-5-methyl-isoxazol-4-oyl]-4-piperidinyl]-1,3-benzenedimethanamine;

(ss) AMD7138, N-[(2-hydroxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~bacteria~~]pyridin-9-yl)-1,4-benzenedimethanamine;

(tt) AMD7140, N-[(4-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~bacteria~~]pyridin-9-yl)-1,4-benzenedimethanamine;

(uu) AMD7141, N-[(4-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(vv) AMD7142, N-[(4-acetamidophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;

(ww) AMD7145, N-[(4-phenoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~bacteria~~]pyridin-9-yl)-1,4-benzenedimethanamine;

(xx) AMD7147, N-[(1-methyl-2-carboxamido)ethyl]-N,N'-bis(2-pyridinylmethyl)-1,3-benzenedimethanamine;

(yy) AMD7151, N-[(4-benzyloxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~bacteria~~]pyridin-9-yl)-1,4-benzenedimethanamine; and

(zz) AMD7155, N-[(thiophene-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~bacteria~~]pyridin-9-yl)-1,4-benzenedimethanamine.

99-101. (canceled)

14
~~102~~. (previously amended): A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 in admixture with at least one pharmaceutically acceptable excipient.

103-118. (canceled)

15

~~119.~~ (previously added; currently amended): A compound of the formula



wherein, W is a nitrogen atom and Y is void;

R^1 to R^7 may be the same or different and are independently hydrogen or straight, branched or cyclic C_{1-6} alkyl;

R^8 is an optionally substituted heterocyclic group or an optionally substituted aromatic group

Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

F1

n and n' are independently, 0-2;

X is a group of the formula:



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted nitrogen atom and wherein any heteroatom in ring A or B is N;

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a $(CH_2)_{n''}$ group (where n''= 1-2), or V is a C=O group; and

wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted C_{1-6} alkyl group; an optionally substituted aromatic or heterocyclic group; ~~a C_{1-6} alkyl group substituted with an optionally substituted aromatic or heterocyclic group;~~ an optionally substituted amino group; an optionally substituted C_{1-6} alkylamino or C_{3-7} cycloalkylamino group; ~~a sulfonyl group~~ and an optionally substituted carbonyl group; or the pharmaceutically acceptable acid addition salts thereof;

including said compound in any stereoisomeric form and any mixture of stereoisomeric forms thereof.

16 15
~~120~~. (previously added): The compound of claim ~~119~~, wherein Ring A is selected from the group consisting of: pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; and triazole and the optionally substituted forms thereof.

F1 17 15
~~121~~. (previously added): The compound of claim ~~119~~, wherein Ring B is selected from the group consisting of: benzene and a 5 to 7–membered cycloalkyl ring; and the optionally substituted forms thereof.

18 15
~~122~~. (previously added): The compound of claim ~~119~~, wherein Ring B is selected from the group consisting of: cyclopentyl; cyclohexyl; cycloheptyl; cyclopentenyl; cyclohexenyl; and cycloheptenyl and the optionally substituted forms thereof.

19 15
~~123~~. (previously added): The compound of claim ~~119~~, wherein Ring A and Ring B together are optionally substituted dihydroquinoline or tetrahydroquinoline.

20 15
~~124~~. (previously added): The compound of claim ~~119~~, wherein Ring A and Ring B are independently optionally substituted with a substituent selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

125. (previously added; previously amended): The compound of claim 119 wherein said optional substituent in Ring A or Ring B is independently an optionally substituted aralkyl or heterocycloalkyl, wherein said heterocycloalkyl is a 5 or 6 membered ring containing 1-4 heteroatoms.

126. (previously added): The compound of claim 125, wherein said optionally substituted aralkyl or heterocycloalkyl is selected from the group consisting of: phenylC_{1-4}alkyl; phenylmethyl (benzyl); phenethyl; pyridinylmethyl; and pyridinylethyl.

127. (previously added): The compound of claim 119, wherein Z is an optionally substituted C_{1-6}alkyl group, wherein said C_{1-6}alkyl group is substituted with one or more substituents selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

128. (previously added): The compound of claim 119, wherein Z is an optionally substituted aromatic or heterocyclic group or a C_{1-6}alkyl group optionally substituted with an optionally substituted aromatic or heterocyclic group.

129. (previously added; previously amended): The compound of claim 128, wherein said optionally substituted aromatic group is substituted with a substituent selected from the group consisting of: benzene; naphthalene; dihydronaphthalene; and tetrahydronaphthalene; and wherein said optionally substituted heterocyclic group is a 5 to 6-membered saturated, partially saturated, or aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.

130. (previously added): The compound of claim 129, wherein said heterocyclic group is selected from the group consisting of: pyridine, quinoline, isoquinoline, imidazole, benzimidazole, azabenzimidazole, benzotriazole, furan, benzofuran, thiazole, benzothiazole, oxazole, benzoxazole, pyrrole, indole, indoline, indazole, pyrrolidine, pyrrolidone, pyrroline,

piperidine, piperazine, tetrahydroquinoline, tetrahydroisoquinoline, pyrazole, thiophene, isoxazole, isothiazole, triazole, tetrazole, oxadiazole, thiadiazole, morpholine, thiamorpholine, pyrazolidine, imidazolidine, imidazoline, tetrahydropyran, dihydropyran, benzopyran, dioxane, dithiane, tetrahydrofuran, tetrahydrothiophene, dihydrofuran, and dihydrothiophene.

27 ~~131~~. (previously added; previously amended): The compound of claim ~~130~~ 26, wherein said heterocyclic group contains nitrogen or sulfur heteroatoms; and wherein said nitrogen or sulfur heteroatoms are optionally in the form of oxides.

28 ~~132~~. (previously added): A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim ~~119~~ 15 in admixture with at least one pharmaceutically acceptable excipient.

29 ~~133~~. (new): The compound of claim 1, wherein Z is a C_{1-6} alkyl group substituted with an optionally substituted aromatic or heterocyclic group.

30 ~~134~~. (new): The compound of claim ~~119~~ 15, wherein Z is a C_{1-6} alkyl group substituted with an optionally substituted aromatic or heterocyclic group.

SPECIFICATION AMENDMENT

Please replace the paragraph on page 7, line 24, with the following rewritten paragraph:

F2 ~~Fig.1~~ Fig. 1A-BBB show structural formulas of compounds of the present invention.